Evergreening is when brand-name pharmaceutical companies patent "new inventions" that are in reality minor modifications of old drugs. These could include new forms of release, new dosages ...

The concept of evergreening refers to a strategy used by pharmaceutical companies to extend the life of patent protection beyond the term of one or more “original” patents. Companies often ...

India’s offer comes in the backdrop of the US administration’s stated desire to sharply reduce local drug prices, and gains ...

This focus on value-based pricing may not only help curb evergreening but also encourage pharmaceutical companies to prioritize the development of truly innovative, high-quality drugs. As shown in ...

To delay the “patent cliff,” pharmaceutical companies prevent generic formation through evergreening. Evergreening is the process in which companies artificially extend the lifetime of their ...

Put simply, evergreening is when a pharma company patents minor modifications on the drug as “new inventions” and then uses the new patents to extend their monopoly, freezing out competition ...

Congress added — and then abruptly dropped — a section of a proposed spending bill aimed at limiting the number of patents pharmaceutical manufacturers could assert in ...

Through evergreening, pharmaceutical companies make alterations to a drug, such as changing its chemical composition slightly or making an external tweak as minor as adding a stripe to a pill with ...

India has offered to supply complex generics at just 20–25 percent of the branded drug prices for the first three years after ...

The case before Judge Collis was about “evergreening”, in which pharmaceutical companies who have patents on medicines extend the life-time of the patent. In the case of rivaroxaban the patent ...

The Global Trade Research Initiative (GTRI) has warned that US President Donald Trump's plan to cut prescription drug prices by 30-80 per cent may lead global pharmaceutical companies to push for ...

Each year, the U.S. government spends over $100 billion investing in the research and development of new technologies, with pharmaceutical companies being among the chief beneficiaries of this ...